What is NDC 0024-5761?

0024-5761 is the product NDC for Soliqua 100/33, Insulin glargine 100 U/mL; Lixisenatide 33 ug/mL injection, solution, listed with the FDA by Sanofi-Aventis U.S. LLC. It has 2 package NDCs, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Soliqua 100/33 (Insulin glargine and lixisenatide).

What is the active ingredient?

Insulin glargine, Lixisenatide.

Sanofi-Aventis U.S. LLC, NDC labeler code 0024. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Soliqua 100/33?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Soliqua 100/33 NDC 0024-5761 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0024-5761Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00024-5761Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0024-5761-01	0002457610100024576101	1 SYRINGE in 1 CARTON (0024-5761-01) / 3 mL in 1 SYRINGEMarketed from Nov 21, 2016
0024-5761-05	0002457610500024576105	5 SYRINGE in 1 CARTON (0024-5761-05) / 3 mL in 1 SYRINGE (0024-5761-02)Marketed from Nov 21, 2016

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Soliqua 100/33
Generic name (nonproprietary): insulin glargine and lixisenatide
Active ingredients: Insulin glargine — 100 U/mLLixisenatide — 33 ug/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Sanofi-Aventis U.S. LLCNDC labeler code 0024
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 208673
Marketing start: Nov 21, 2016
Listing expires: Dec 31, 2027
Other FDA classes: Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)Insulin (Chemical structure)
Identifiers: Product ID 0024-5761_dd3cca75-32f2-4e6d-8121-20f47e101495SPL ID dd3cca75-32f2-4e6d-8121-20f47e101495SPL set ID 4bba538b-cf7c-4310-ae8f-cb711ed21bccRxCUI 1858995, 1859000UNII 2ZM8CX04RZ, 74O62BB01U
Pharmacologic class: GLP-1 Receptor Agonist; Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400024576101 followed by a unit qualifier and the quantity

Package 00024-5761-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 18, 2026.

Indications (excerpt from the label)

SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use ( 1 ) : Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended. Not recommended for the treatment of diabetic ketoacidosis. Has not been studied in combination with prandial i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0024-5761

What is NDC 0024-5761?: 0024-5761 is the product NDC for Soliqua 100/33, Insulin glargine 100 U/mL; Lixisenatide 33 ug/mL injection, solution, listed with the FDA by Sanofi-Aventis U.S. LLC. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Soliqua 100/33 (Insulin glargine and lixisenatide).
What is the active ingredient?: Insulin glargine, Lixisenatide.
Who is the labeler?: Sanofi-Aventis U.S. LLC, NDC labeler code 0024. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Soliqua 100/33?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Soliqua 100/33 (Insulin glargine and lixisenatide) NDC 0024-5761